Movement Alert｜Natera Rises 3.05% in Regular Trading, Multi-Cancer Early Detection Assay Granted FDA Breakthrough Device Designation

Market Focus10-09

On October 9, Natera rose 3.05% in regular trading, trading at $402.51/share, with Turnover of $20.36 million.

The move was driven by news that the company's multi-cancer early detection assay has been granted Breakthrough Device Designation by the US Food and Drug Administration. The designation is intended to speed up development, assessment, review, and marketing authorization of medical devices.

The assay works by analyzing cell-free DNA in the blood to screen for multiple cancers. The catalyst follows a period of profit-taking after earlier gains tied to the launch of a phase 3 breast cancer trial, and comes amid recent analyst target price increases, including RBC's raise to $460.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment